Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas

Inclusion Criteria

• •Informed consent.
• •EBV-positive lymphoma as determined by in situ hybridization or equivalent (excluding Burkitts Lymphoma).
• •Age 18 years or older.
• •ECOG performance status 1, 2 or 3
• •Life expectancy of at least 6 months.
• •Measurable disease: either relapsing, partially responsive, refractory or progressive disease, includes disease detected either by clinical examination, radiographic evaluation (including CT scans, and at physician's discretion by functional imaging), or a persistently detectable plasma EBV viral load.
• •No chemotherapy / radiotherapy and/or antibody therapy for at least 2 weeks prior to anticipated date of first infusion.